Please ensure Javascript is enabled for purposes of website accessibility

Tag Archives: synthetic biologics

Rockville pharma gets generic drug name approved (access required)

A Rockville firm has received approval for a generic name for a drug it is developing to combat the unintended consequences of antibiotic use. The U.S. Adopted Names Council has approved the name “ribaxamase” for Synthetic Biologics Inc.’s drug candidate, which ...

Read More »

Md. firm set to present to investors in NY (access required)

Synthetic Biologics Inc., a Rockville-based biotechnology company, plans to make a pitch to investors next week. Jeffrey Riley, the firm’s president and CEO, is scheduled to speak at 3 p.m. July 13 at the Cantor Fitzgerald Healthcare Conference. The conference, set to ...

Read More »

Synthetic Biologics posts bigger loss (access required)

Synthetic Biologics, a Rockville-based biotechnology company, reported a $7.5 million increase in net loss for 2014. Synthetic Biologics posted a net loss of $19.8 million, or 32 cents per share, for 2014, compared with $12.3 million and 27 cents for ...

Read More »

Rockville biotech raises $20.7M

Synthetic Biologics Inc., Rockville-based biotechnology company, recently sold 14.1 million units — each consisting of a share of common stock and a warrant to purchase a half-share — to select institutional investors for approximately $20.7 million. The units sold at ...

Read More »

Synthetic Biologics gets orphan drug tag

Synthetic Biologics Inc., of Rockville, a biotechnology company, announced Friday that the Food and Drug Administration has granted orphan drug designation to the company’s proprietary SYN-005 product for the treatment of pertussis, more commonly known as whooping cough. Orphan drug ...

Read More »

Synthetic Biologics product advances

Synthetic Biologics Inc., of Rockville, a biotechnology company focused on the development of treatments to halt pathogens that cause serious infections and diseases, announced positive results on Tuesday from its final preclinical toxicology study of SYN-004. The product is an ...

Read More »

Synthetic Biologics reports larger loss (access required)

Synthetic Biologics Inc., of Rockville, which develops and commercializes medicines for the treatment of serious infectious diseases, reported its first-quarter net loss totaled $2.2 million, or 5 cents per diluted share, compared with a net loss of $1.2 million, or 4 cents per diluted share, for the year-ago period.

Read More »

Rockville company’s drug to be tested in U.S.

Synthetic Biologics Inc., of Rockville, which develops and commercializes medicines derived from synthetic biology, said its Swedish sublicensee, Meda AB, received approval from U.S. regulators to conduct a Phase II study of a new drug being developed for the treatment of fibromyalgia.

Read More »